Collegium Pharmaceutical, Inc. (COLL) Reaches $16.66 After 7.00% Down Move; Eco Ventures Group (GEUR)’s Sentiment Is 2

December 6, 2017 - By Louis Casey

The ETF increased 0.52% or $0.06 during the last trading session, reaching $11.74. It is down 8.29% since December 6, 2016 and is downtrending. It has underperformed by 24.99% the S&P500.

The stock of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is a huge mover today! The stock decreased 6.09% or $1.08 during the last trading session, reaching $16.66. About 502,354 shares traded. Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has declined 44.24% since December 6, 2016 and is downtrending. It has underperformed by 60.94% the S&P500.The move comes after 6 months negative chart setup for the $542.49M company. It was reported on Dec, 6 by Barchart.com. We have $15.49 PT which if reached, will make NASDAQ:COLL worth $37.97M less.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. The company has market cap of $542.49 million. It offers Xtampza, an oral formulation of oxycodone, for the management of pain. It currently has negative earnings. The firm also develops Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older.

Analysts await Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to report earnings on March, 8. They expect $-0.57 EPS, up 44.12% or $0.45 from last year’s $-1.02 per share. After $-0.45 actual EPS reported by Collegium Pharmaceutical, Inc. for the previous quarter, Wall Street now forecasts 26.67% negative EPS growth.

Among 7 analysts covering Collegium Pharmaceutical Inc (NASDAQ:COLL), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Collegium Pharmaceutical Inc had 13 analyst reports since February 19, 2016 according to SRatingsIntel. The stock of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has “Buy” rating given on Wednesday, November 29 by Piper Jaffray. On Tuesday, July 25 the stock rating was maintained by Piper Jaffray with “Buy”. Jefferies maintained it with “Buy” rating and $1500 target in Monday, June 12 report. The firm has “Buy” rating given on Wednesday, August 16 by Jefferies. The rating was initiated by William Blair with “Outperform” on Friday, February 19. The rating was maintained by Jefferies with “Buy” on Wednesday, October 18. The stock of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has “Buy” rating given on Friday, June 9 by Needham. The stock of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has “Buy” rating given on Tuesday, September 13 by Gabelli. The firm earned “Buy” rating on Friday, June 9 by Janney Capital. The company was maintained on Friday, July 14 by Jefferies.

Rothschild Investment Corp Il holds 0.03% of its portfolio in AdvisorShares Gartman Gold/Euro ETF for 25,035 shares. Hbk Sorce Advisory Llc owns 12,203 shares or 0.02% of their US portfolio. Moreover, Jane Street Group Llc has 0% invested in the company for 65,300 shares. The California-based Lpl Financial Llc has invested 0% in the stock. Next Financial Group Inc, a Texas-based fund reported 200 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com